- Home
- PLSE vs MLTX Comparison
PLSE vs MLTX Comparison
Compare PLSE & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | MLTX |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLSE | MLTX |
|---|---|---|
| Price | $25.60 | $20.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $22.00 | ★ $27.50 |
| AVG Volume (30 Days) | 336.0K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $5.95 |
| 52 Week High | $31.00 | $62.75 |
Technical Indicators
Market Signals| Indicator | PLSE | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 56.62 |
| Support Level | $23.94 | $15.89 |
| Resistance Level | $27.82 | $21.00 |
| Average True Range (ATR) | 1.78 | 0.85 |
| MACD | -0.37 | 0.01 |
| Stochastic Oscillator | 11.58 | 57.80 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.